Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS Australia (SA) Inc
 
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 3104

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 28,
Hindmarsh,
South Australia 5007

Office:
Suite 506,
North Terrace House,
19 North Terrace,
Hackney, SA, 5069


Phone:
1300 128 339

Office Hours:
Wednesdays, 11am-3pm

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form (PDF, 242KB)
Why become a member?

Effects of sodium oxybate for Fibromyalgia maintained in long-term study

Sunday 29 December 2013

 

From ProHealth:

 

Tablets
 

Effects of Sodium Oxybate for Fibromyalgia Maintained in Long-Term Study

www.ProHealth.com • December 22, 2013

Note: You may read the full text of this article free HERE.

Editor's comment: In October 2010, the FDA turned down Jazz Pharmaceuticals' request for approval of sodium oxybate for the treatment of fibromyalgia, citing safety concerns. They expressed particular concerns about the potential for abuse or misuse of the medication.

Sodium oxybate is currently approved for the treatment of excessive daytime sleepiness and cataplexy (the sudden loss of muscle tone) in adult patients with narcolepsy. It's use is monitored by an extremely stringent safety plan – an even more restrictive plan than is used for opioids. Sodium oxybate is classified as a Schedule III drug and its distribution is restricted through the Patient Success Program. It can only be purchased from one central, mail-order pharmacy and patients are first required to read a letter and brochure as well as watch a video about the medication.

One of the reasons the FDA has such serious concerns is likely because sodium oxybate, also known as gamma-hydroxybutyrate (GHB), is known to have been used as a date rape drug in the past. In an effort to address the FDA's concerns, Jazz Pharmaceuticals is conducting additional studies on the safety and efficacy of sodium oxybate for FM. This study looked at the long-term effectiveness and tolerability of the drug.

Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia.

By Michael Spaeth, et al.

Abstract:

INTRODUCTION: The long-term safety and therapeutic response of sodium oxybate (SXB) in fibromyalgia syndrome (FM) patients were assessed for a combined period of up to 1 year in a prospective, multicenter, open-label, extension study in patients completing 1 of 2 phase 3 randomized, double-blind, controlled, 14-week trials that examined the efficacy and safety of SXB 4.5 g, SXB 6 g, and placebo for treatment of FM.

METHODS: This extension study comprised an additional 38 weeks of treatment and was carried out at 130 clinical sites in 7 countries. Initial entry criteria for the previous 2 double-blind clinical trials required that patients aged ≥ 18 years met the American College of Rheumatology 1990 criteria for FM, had a body mass index (BMI) < 40 kg/m2, and had a score ≥ 50 on a 100-mm pain visual analog scale (VAS) at baseline. All patients began treatment in the extension study with SXB 4.5 g/night (administered in 2 equally divided doses) for at least 1 week, followed by possible serial 1.5 g/night dose increases to 9 g/night (maximum) or reductions to 4.5 g/night (minimum).

RESULTS: Of the 560 FM patients enrolled in this extension study, 319 (57.0%) completed the study. The main reason for early discontinuation was adverse events (AEs; 23.0% of patients). Patients were primarily middle-aged (mean 46.9 ± 10.8 years), female (91.1%), white (91.4%), with a mean duration of FM symptoms of 9.9 ± 8.7 years.

  • Serious AEs were experienced by 3.6% of patients.

  • The most frequently reported AEs (incidence ≥ 5% at any dose or overall) were nausea, headache, dizziness, nasopharyngitis, vomiting, sinusitis, diarrhea, anxiety, insomnia, influenza, somnolence, upper respiratory tract infection, muscle spasms, urinary tract infection, and gastroenteritis viral.

  • Maintenance of SXB therapeutic response was demonstrated with continued improvement from controlled-study baseline in pain VAS, Fibromyalgia Impact Questionnaire (FIQ) total scores, and other measures.

  • Responder analyses showed that 68.8% of patients achieved ≥ 30% reduction in pain VAS and 69.7% achieved ≥ 30% reduction in FIQ total score at study endpoint.

CONCLUSIONS: The long-term safety profile of SXB in FM patients was similar to that in the previously reported controlled clinical trials. Improvement in pain and other FM clinical domains was maintained during long-term use.

Source: Arthritis Research & Therapy, November 11, 2013. By Michael Spaeth, Cayetano Alegre, Serge Perrot, Youyu Grace Wang, Diane R Guinta, Sarah Alvarez-Horine, Irwin Jon Russell and the Sodium Oxybate Fibromyalgia Study Group.

 

The above originally appeared here.

 


Arrow right

More Fibromyalgia News

 


 

blog comments powered by Disqus
Previous Previous Page